Quick Read Pfizer (PFE) offers a rare combination of a 6.5% dividend yield with a promising pipeline of oncology treatments and a new Lyme disease vaccine, trading at 9.1x forward P/E despite being 55% below its 2021 peak. Patent expirations through 2026 are dragging down revenue expectations, but the company’s Antibody-Drug Conjugate cancer candidates in Phase 2 and 3 trials and its $10 billion oncology revenue goal by 2030 could offset the decline if successful. Have You read The New Report Shaking ...

This 6.5%Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In By Joey FrenettePublished Mar 25, 12:23PM EDT Quick Read This 6.5%Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In - 24/7 Wall St. S&P 5006,618.40 +0.13% Dow Jones46,569.80 +0.19% Nasdaq 10024,276.20 +0.16% Russell 20002,540.42 +0.13% FTSE 10010,119.80 +1.03% Nikkei 22553,960.50 +1.09% Stock Market Live March 25, 2026: S&P 500 (SPY) Roller Coaster Ride Continues Investing Pfizer (PFE) of ...

I've been researching companies in-depth for over a decade, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emerging market stocks, which I believe could help me provide useful content for readers. After writing my own blog for about 3 years, I decided to switch to a value investing-focused YouTube channel, where I researched hundreds of different companies so far. I would say my favorite type of company to cover are metals and mining stocks, but I am comfortabl ...

I believe that Pfizer ( PFE ) is one of the companies that I’ve covered the most here on Seeking Alpha , as I believe that it has some of the best valueAs a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjustified reasons that coul ...

Key Takeaways VALN stock dropped 37% after its Lyme vaccine missed a key statistical benchmark in a phase III study.Valneva reported 73.2% efficacy at 28 days, but the confidence interval fell below the required threshold.PF-07307405 showed 74.8% efficacy in a second analysis, supporting planned global filings.Shares of Valneva (VALN) tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which evaluated its experimental Lyme disease vaccine, PF-07307405 (formerly V ...

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial - 24/7 Wall St. Russell 20002,502.44 +0.30% FTSE 1009,953.60 -0.04% Nikkei 22552,743.00 -1.01% Stock Market Live March 24, 2026: S&P 500 (SPY) Under Pressure Again Investing S&P 5006,579.90 -0.18% Dow Jones46,338.00 +0.13% Nasdaq 10024,091.00 -0.55% Pfizer Could Hit $36 by Year-End as Analysts See 2- to-1 Payoff on Key Prostate Cancer Trial By Joel SouthPublished Mar 24, 10:52AM EDT Quick Read Pfizer (PFE) is trading ...

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investorswithin 24 hours after the end of the live conference call and will be accessible for at least 90 days. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bri ...

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost confidence in the company's ability to grow, as it loses patent protection on key drugs and faces an uncertain future. Besides a dividend, there hasn't been a compelling reason for investors to buy shares of Pfizer. But this year, with there being more concern in the markets and investors piling into dividend stock ...

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades. ...

The Best Marijuana Stocks For Better InvestingMarijuana stock investors remain optimistic and focused on the future. The potential for significant gains with cannabis stocks as a long-term investment is where the value lies. With all that has taken place, the sector is still battling low-level trading and high amounts of volatility. Now, as things further progress for legal operators, this gives hope and positive speculation for investors. Right now, more companies are working to not just resolve and improv ...